Effect of secukinumab on quality of life and psoriasis-related symptoms: a comparative analysis versus ustekinumab from the CLEAR 52-week study
BACKGROUND: Secukinumab has demonstrated greater sustained skin clearance versus ustekinumab through Week 52, greater improvement in symptoms and health-related quality of life (HRQOL), and comparable safety profile.
OBJECTIVE: To assess the impact of secukinumab versus ustekinumab on complete relief from psoriasis-related symptoms, time to HRQOL response, and cumulative benefit among patients with moderate-to-severe plaque psoriasis.
METHODS: Psoriasis-related pain, itching, and scaling and the Dermatology Life Quality Index (DLQI) were compared between treatments based on time to complete relief of symptoms and to DLQI response in the CLEAR trial. Cumulative benefit over 52 weeks based on Psoriasis Area and Severity Index (PASI), symptom relief, and DLQI response was evaluated using area-under-the-curve analysis.
RESULTS: Significantly more patients treated with secukinumab achieved complete relief of pain at Week 16 and 52 (all P < 0.05). Complete relief of itching and scaling occurred significantly faster for secukinumab (median: 4 weeks faster for itching, 8 weeks faster for scaling; P < 0.001). DLQI response was 4 weeks faster for secukinumab (P < 0.0001). Cumulative benefits were greater for secukinumab (all P < 0.05).
LIMITATIONS: Analyses were post-hoc.
CONCLUSION: This patient-reported-outcome analysis confirms greater and sustained benefits of secukinumab versus ustekinumab treatment on patients' lives.